STOCK TITAN

Delcath Systems to Host Third Quarter 2024 Earnings Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Delcath Systems (Nasdaq: DCTH), an interventional oncology company specializing in liver cancer treatments, has announced it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss its third quarter 2024 financial results. The call will be accessible via toll-free and international dial-in numbers, with a webcast option available. A replay will be archived on the company's website after the event.

Delcath Systems (Nasdaq: DCTH), un'azienda specializzata in oncologia interventistica e trattamenti per il cancro al fegato, ha annunciato che terrà una conferenza telefonica l'8 novembre 2024 alle 8:30 ora orientale per discutere i risultati finanziari del terzo trimestre 2024. La chiamata sarà accessibile tramite numeri verdi e internazionali, con un'opzione di webcast disponibile. Una registrazione sarà archiviata sul sito web dell'azienda dopo l'evento.

Delcath Systems (Nasdaq: DCTH), una empresa de oncología intervencionista especializada en tratamientos para el cáncer de hígado, ha anunciado que llevará a cabo una conferencia telefónica el 8 de noviembre de 2024 a las 8:30 AM, hora del Este, para discutir sus resultados financieros del tercer trimestre de 2024. La llamada será accesible a través de números gratuitos e internacionales, con una opción de webcast disponible. Se archivará una grabación en el sitio web de la empresa después del evento.

Delcath Systems (Nasdaq: DCTH)는 간암 치료를 전문으로 하는 중재적 종양학 회사로서 2024년 11월 8일 오전 8시 30분 동부 표준시(Eastern Time)로 2024년 3분기 재무 결과에 대해 논의하는 컨퍼런스 콜을 진행한다고 발표했습니다. 이 콜은 무료 및 국제 전화 접속 번호를 통해 참여할 수 있으며, 웹캐스트 옵션도 제공됩니다. 이벤트 후 회사 웹사이트에 재생 기록이 저장될 예정입니다.

Delcath Systems (Nasdaq: DCTH), une entreprise d'oncologie interventionnelle spécialisée dans les traitements du cancer du foie, a annoncé qu'elle tiendra une conférence téléphonique le 8 novembre 2024 à 8h30, heure de l'Est, pour discuter de ses résultats financiers du troisième trimestre 2024. L'appel sera accessible par des numéros d'appel gratuits et internationaux, avec une option de webdiffusion disponible. Un enregistrement sera archivé sur le site Web de l'entreprise après l'événement.

Delcath Systems (Nasdaq: DCTH), ein Unternehmen für interventionelle Onkologie, das sich auf die Behandlung von Leberkrebs spezialisiert hat, gab bekannt, dass am 8. November 2024 um 8:30 Uhr Eastern Time eine Telefonkonferenz stattfinden wird, um die finanziellen Ergebnisse des dritten Quartals 2024 zu besprechen. Der Anruf wird über gebührenfreie und internationale Telefonnummern zugänglich sein, mit einer verfügbaren Webcast-Option. Eine Aufzeichnung wird nach der Veranstaltung auf der Website des Unternehmens archiviert.

Positive
  • None.
Negative
  • None.

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2024.

Conference Call Information

To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.

Event Date: Friday, November 8, 2024
Time: 8:30 AM Eastern Time

Participant Numbers:
Toll Free: 1-877-407-3982
International: 1-201-493-6780
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691899&tp_key=9d94cb0736

A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website here.

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Investor Relations Contact:

ICR Healthcare

investorrelations@delcath.com

Source: Delcath Systems, Inc.

FAQ

When is Delcath Systems (DCTH) Q3 2024 earnings call?

Delcath Systems (DCTH) will host its Q3 2024 earnings call on November 8, 2024, at 8:30 AM Eastern Time.

How can I access Delcath Systems (DCTH) Q3 2024 earnings call?

You can access the call through toll-free number 1-877-407-3982, international number 1-201-493-6780, or via webcast at the company's website.

Will there be a replay available for Delcath Systems (DCTH) Q3 2024 earnings call?

Yes, a replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

Delcath Systems Inc

NASDAQ:DCTH

DCTH Rankings

DCTH Latest News

DCTH Stock Data

313.66M
29.73M
2.71%
38.13%
4.46%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
QUEENSBURY